nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—L-Phenylalanine—Liothyronine—hypothyroidism	0.584	1	CrCrCtD
Amphetamine—CARTPT—nerve—hypothyroidism	0.0169	0.136	CbGeAlD
Amphetamine—Muscle twitching—Liothyronine—hypothyroidism	0.00991	0.0482	CcSEcCtD
Amphetamine—CARTPT—adrenal cortex—hypothyroidism	0.00649	0.0523	CbGeAlD
Amphetamine—CARTPT—Circadian rythm related genes—NKX2-1—hypothyroidism	0.00609	0.0706	CbGpPWpGaD
Amphetamine—Acute coronary syndrome—Liothyronine—hypothyroidism	0.00536	0.0261	CcSEcCtD
Amphetamine—Myocardial infarction—Liothyronine—hypothyroidism	0.00533	0.026	CcSEcCtD
Amphetamine—CARTPT—pituitary gland—hypothyroidism	0.00524	0.0423	CbGeAlD
Amphetamine—CARTPT—adrenal gland—hypothyroidism	0.00468	0.0378	CbGeAlD
Amphetamine—CARTPT—blood—hypothyroidism	0.00468	0.0377	CbGeAlD
Amphetamine—TAAR1—thyroid gland—hypothyroidism	0.00452	0.0364	CbGeAlD
Amphetamine—CARTPT—thyroid gland—hypothyroidism	0.00452	0.0364	CbGeAlD
Amphetamine—SLC6A3—nerve—hypothyroidism	0.00435	0.035	CbGeAlD
Amphetamine—SLC18A2—Amine compound SLC transporters—SLC5A7—hypothyroidism	0.00432	0.0501	CbGpPWpGaD
Amphetamine—SLC22A3—tongue—hypothyroidism	0.004	0.0322	CbGeAlD
Amphetamine—CARTPT—testis—hypothyroidism	0.00387	0.0312	CbGeAlD
Amphetamine—MAOB—nerve—hypothyroidism	0.00379	0.0305	CbGeAlD
Amphetamine—Hypertension—Liothyronine—hypothyroidism	0.00367	0.0179	CcSEcCtD
Amphetamine—Muscle twitching—Liotrix—hypothyroidism	0.00358	0.0174	CcSEcCtD
Amphetamine—CARTPT—cerebellum—hypothyroidism	0.00358	0.0288	CbGeAlD
Amphetamine—SLC6A2—nerve—hypothyroidism	0.00351	0.0283	CbGeAlD
Amphetamine—Affect lability—Levothyroxine—hypothyroidism	0.00341	0.0166	CcSEcCtD
Amphetamine—Affect lability—Dextrothyroxine—hypothyroidism	0.00341	0.0166	CcSEcCtD
Amphetamine—Tachycardia—Liothyronine—hypothyroidism	0.00339	0.0165	CcSEcCtD
Amphetamine—Irritability—Levothyroxine—hypothyroidism	0.00331	0.0161	CcSEcCtD
Amphetamine—Irritability—Dextrothyroxine—hypothyroidism	0.00331	0.0161	CcSEcCtD
Amphetamine—SLC18A2—Neurotransmitter Release Cycle—SLC5A7—hypothyroidism	0.0033	0.0383	CbGpPWpGaD
Amphetamine—Mood swings—Dextrothyroxine—hypothyroidism	0.00328	0.016	CcSEcCtD
Amphetamine—Mood swings—Levothyroxine—hypothyroidism	0.00328	0.016	CcSEcCtD
Amphetamine—SLC6A4—Monoamine Transport—SLC5A7—hypothyroidism	0.00321	0.0372	CbGpPWpGaD
Amphetamine—DRD2—nerve—hypothyroidism	0.00319	0.0257	CbGeAlD
Amphetamine—Lightheadedness—Liotrix—hypothyroidism	0.00314	0.0153	CcSEcCtD
Amphetamine—SLC6A2—Amine compound SLC transporters—SLC5A7—hypothyroidism	0.00291	0.0337	CbGpPWpGaD
Amphetamine—CYP2D6—urine—hypothyroidism	0.00278	0.0224	CbGeAlD
Amphetamine—SLC6A2—Monoamine Transport—SLC5A7—hypothyroidism	0.00276	0.032	CbGpPWpGaD
Amphetamine—Body temperature increased—Liothyronine—hypothyroidism	0.00274	0.0134	CcSEcCtD
Amphetamine—Weight decreased—Dextrothyroxine—hypothyroidism	0.00271	0.0132	CcSEcCtD
Amphetamine—Weight decreased—Levothyroxine—hypothyroidism	0.00271	0.0132	CcSEcCtD
Amphetamine—Acute coronary syndrome—Dextrothyroxine—hypothyroidism	0.00263	0.0128	CcSEcCtD
Amphetamine—Acute coronary syndrome—Levothyroxine—hypothyroidism	0.00263	0.0128	CcSEcCtD
Amphetamine—Myocardial infarction—Levothyroxine—hypothyroidism	0.00262	0.0128	CcSEcCtD
Amphetamine—Myocardial infarction—Dextrothyroxine—hypothyroidism	0.00262	0.0128	CcSEcCtD
Amphetamine—Cerebrovascular accident—Liotrix—hypothyroidism	0.0026	0.0127	CcSEcCtD
Amphetamine—SLC6A3—Amine compound SLC transporters—SLC5A7—hypothyroidism	0.00258	0.0299	CbGpPWpGaD
Amphetamine—Sweating—Dextrothyroxine—hypothyroidism	0.00256	0.0125	CcSEcCtD
Amphetamine—Sweating—Levothyroxine—hypothyroidism	0.00256	0.0125	CcSEcCtD
Amphetamine—Affect lability—Liotrix—hypothyroidism	0.00251	0.0122	CcSEcCtD
Amphetamine—SLC6A3—Monoamine Transport—SLC5A7—hypothyroidism	0.00245	0.0284	CbGpPWpGaD
Amphetamine—Irritability—Liotrix—hypothyroidism	0.00243	0.0119	CcSEcCtD
Amphetamine—Mood swings—Liotrix—hypothyroidism	0.00242	0.0118	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—AVP—hypothyroidism	0.00231	0.0268	CbGpPWpGaD
Amphetamine—Tension—Dextrothyroxine—hypothyroidism	0.00205	0.00998	CcSEcCtD
Amphetamine—Tension—Levothyroxine—hypothyroidism	0.00205	0.00998	CcSEcCtD
Amphetamine—Nervousness—Dextrothyroxine—hypothyroidism	0.00203	0.00988	CcSEcCtD
Amphetamine—Nervousness—Levothyroxine—hypothyroidism	0.00203	0.00988	CcSEcCtD
Amphetamine—Weight decreased—Liotrix—hypothyroidism	0.00199	0.00971	CcSEcCtD
Amphetamine—SLC18A2—Synaptic Vesicle Pathway—CLTC—hypothyroidism	0.00196	0.0227	CbGpPWpGaD
Amphetamine—Tremor—Levothyroxine—hypothyroidism	0.00196	0.00953	CcSEcCtD
Amphetamine—Tremor—Dextrothyroxine—hypothyroidism	0.00196	0.00953	CcSEcCtD
Amphetamine—Acute coronary syndrome—Liotrix—hypothyroidism	0.00194	0.00944	CcSEcCtD
Amphetamine—Myocardial infarction—Liotrix—hypothyroidism	0.00193	0.00938	CcSEcCtD
Amphetamine—Agitation—Dextrothyroxine—hypothyroidism	0.00192	0.00935	CcSEcCtD
Amphetamine—Agitation—Levothyroxine—hypothyroidism	0.00192	0.00935	CcSEcCtD
Amphetamine—Angioedema—Levothyroxine—hypothyroidism	0.00191	0.00929	CcSEcCtD
Amphetamine—Angioedema—Dextrothyroxine—hypothyroidism	0.00191	0.00929	CcSEcCtD
Amphetamine—Sweating—Liotrix—hypothyroidism	0.00188	0.00918	CcSEcCtD
Amphetamine—Palpitations—Levothyroxine—hypothyroidism	0.00185	0.00899	CcSEcCtD
Amphetamine—Palpitations—Dextrothyroxine—hypothyroidism	0.00185	0.00899	CcSEcCtD
Amphetamine—Convulsion—Dextrothyroxine—hypothyroidism	0.00181	0.00881	CcSEcCtD
Amphetamine—Convulsion—Levothyroxine—hypothyroidism	0.00181	0.00881	CcSEcCtD
Amphetamine—Anxiety—Levothyroxine—hypothyroidism	0.00177	0.00863	CcSEcCtD
Amphetamine—Anxiety—Dextrothyroxine—hypothyroidism	0.00177	0.00863	CcSEcCtD
Amphetamine—SLC22A3—Synaptic Vesicle Pathway—CLTC—hypothyroidism	0.0017	0.0196	CbGpPWpGaD
Amphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.00169	0.0196	CbGpPWpGaD
Amphetamine—Tachycardia—Dextrothyroxine—hypothyroidism	0.00166	0.0081	CcSEcCtD
Amphetamine—Tachycardia—Levothyroxine—hypothyroidism	0.00166	0.0081	CcSEcCtD
Amphetamine—Hyperhidrosis—Dextrothyroxine—hypothyroidism	0.00165	0.00803	CcSEcCtD
Amphetamine—Hyperhidrosis—Levothyroxine—hypothyroidism	0.00165	0.00803	CcSEcCtD
Amphetamine—SLC18A2—adrenal gland—hypothyroidism	0.00159	0.0128	CbGeAlD
Amphetamine—SLC18A2—blood—hypothyroidism	0.00159	0.0128	CbGeAlD
Amphetamine—Insomnia—Levothyroxine—hypothyroidism	0.00154	0.00751	CcSEcCtD
Amphetamine—Insomnia—Dextrothyroxine—hypothyroidism	0.00154	0.00751	CcSEcCtD
Amphetamine—SLC18A2—thyroid gland—hypothyroidism	0.00154	0.0124	CbGeAlD
Amphetamine—SLC6A4—Synaptic Vesicle Pathway—CLTC—hypothyroidism	0.00153	0.0178	CbGpPWpGaD
Amphetamine—TAAR1—G alpha (s) signalling events—TSHB—hypothyroidism	0.00152	0.0176	CbGpPWpGaD
Amphetamine—TAAR1—G alpha (s) signalling events—TSHR—hypothyroidism	0.00152	0.0176	CbGpPWpGaD
Amphetamine—Dyspnoea—Levothyroxine—hypothyroidism	0.00152	0.0074	CcSEcCtD
Amphetamine—Dyspnoea—Dextrothyroxine—hypothyroidism	0.00152	0.0074	CcSEcCtD
Amphetamine—Tension—Liotrix—hypothyroidism	0.00151	0.00734	CcSEcCtD
Amphetamine—Nervousness—Liotrix—hypothyroidism	0.00149	0.00727	CcSEcCtD
Amphetamine—Fatigue—Dextrothyroxine—hypothyroidism	0.00147	0.00716	CcSEcCtD
Amphetamine—Fatigue—Levothyroxine—hypothyroidism	0.00147	0.00716	CcSEcCtD
Amphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.00146	0.0169	CbGpPWpGaD
Amphetamine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.00146	0.0169	CbGpPWpGaD
Amphetamine—MAOB—adrenal cortex—hypothyroidism	0.00145	0.0117	CbGeAlD
Amphetamine—Tremor—Liotrix—hypothyroidism	0.00144	0.00701	CcSEcCtD
Amphetamine—Agitation—Liotrix—hypothyroidism	0.00141	0.00688	CcSEcCtD
Amphetamine—MAOB—heart—hypothyroidism	0.00141	0.0113	CbGeAlD
Amphetamine—Angioedema—Liotrix—hypothyroidism	0.0014	0.00684	CcSEcCtD
Amphetamine—Gastrointestinal pain—Dextrothyroxine—hypothyroidism	0.00139	0.00679	CcSEcCtD
Amphetamine—Gastrointestinal pain—Levothyroxine—hypothyroidism	0.00139	0.00679	CcSEcCtD
Amphetamine—Palpitations—Liotrix—hypothyroidism	0.00136	0.00661	CcSEcCtD
Amphetamine—Urticaria—Dextrothyroxine—hypothyroidism	0.00135	0.00659	CcSEcCtD
Amphetamine—Urticaria—Levothyroxine—hypothyroidism	0.00135	0.00659	CcSEcCtD
Amphetamine—Abdominal pain—Levothyroxine—hypothyroidism	0.00135	0.00656	CcSEcCtD
Amphetamine—Body temperature increased—Dextrothyroxine—hypothyroidism	0.00135	0.00656	CcSEcCtD
Amphetamine—Body temperature increased—Levothyroxine—hypothyroidism	0.00135	0.00656	CcSEcCtD
Amphetamine—Abdominal pain—Dextrothyroxine—hypothyroidism	0.00135	0.00656	CcSEcCtD
Amphetamine—Convulsion—Liotrix—hypothyroidism	0.00133	0.00648	CcSEcCtD
Amphetamine—MAOB—cardiovascular system—hypothyroidism	0.00133	0.0107	CbGeAlD
Amphetamine—Hypertension—Liotrix—hypothyroidism	0.00133	0.00646	CcSEcCtD
Amphetamine—SLC18A2—testis—hypothyroidism	0.00132	0.0106	CbGeAlD
Amphetamine—Chest pain—Liotrix—hypothyroidism	0.00131	0.00637	CcSEcCtD
Amphetamine—Anxiety—Liotrix—hypothyroidism	0.0013	0.00635	CcSEcCtD
Amphetamine—SLC22A3—gonad—hypothyroidism	0.0013	0.0105	CbGeAlD
Amphetamine—Anaphylactic shock—Liotrix—hypothyroidism	0.00125	0.00611	CcSEcCtD
Amphetamine—Infection—Liotrix—hypothyroidism	0.00125	0.00607	CcSEcCtD
Amphetamine—SLC18A2—liver—hypothyroidism	0.00124	0.01	CbGeAlD
Amphetamine—Tachycardia—Liotrix—hypothyroidism	0.00122	0.00596	CcSEcCtD
Amphetamine—Asthenia—Dextrothyroxine—hypothyroidism	0.00122	0.00596	CcSEcCtD
Amphetamine—Asthenia—Levothyroxine—hypothyroidism	0.00122	0.00596	CcSEcCtD
Amphetamine—SLC18A2—cerebellum—hypothyroidism	0.00122	0.0098	CbGeAlD
Amphetamine—Hyperhidrosis—Liotrix—hypothyroidism	0.00121	0.0059	CcSEcCtD
Amphetamine—Anorexia—Liotrix—hypothyroidism	0.00119	0.00582	CcSEcCtD
Amphetamine—MAOB—pituitary gland—hypothyroidism	0.00117	0.00946	CbGeAlD
Amphetamine—Diarrhoea—Levothyroxine—hypothyroidism	0.00117	0.00568	CcSEcCtD
Amphetamine—Diarrhoea—Dextrothyroxine—hypothyroidism	0.00117	0.00568	CcSEcCtD
Amphetamine—SLC22A5—adrenal cortex—hypothyroidism	0.00114	0.0092	CbGeAlD
Amphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.00114	0.0132	CbGpPWpGaD
Amphetamine—Insomnia—Liotrix—hypothyroidism	0.00113	0.00552	CcSEcCtD
Amphetamine—SLC22A3—adrenal gland—hypothyroidism	0.00113	0.00914	CbGeAlD
Amphetamine—Dyspnoea—Liotrix—hypothyroidism	0.00112	0.00544	CcSEcCtD
Amphetamine—SLC6A2—gonad—hypothyroidism	0.00111	0.00898	CbGeAlD
Amphetamine—CYP2A6—liver—hypothyroidism	0.00111	0.00896	CbGeAlD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—DLX2—hypothyroidism	0.00111	0.0129	CbGpPWpGaD
Amphetamine—SLC22A5—heart—hypothyroidism	0.0011	0.0089	CbGeAlD
Amphetamine—SLC6A4—blood—hypothyroidism	0.0011	0.00889	CbGeAlD
Amphetamine—SLC22A3—thyroid gland—hypothyroidism	0.00109	0.00882	CbGeAlD
Amphetamine—Decreased appetite—Liotrix—hypothyroidism	0.00109	0.00531	CcSEcCtD
Amphetamine—CYP2A6—cerebellum—hypothyroidism	0.00109	0.00875	CbGeAlD
Amphetamine—Vomiting—Levothyroxine—hypothyroidism	0.00108	0.00528	CcSEcCtD
Amphetamine—Vomiting—Dextrothyroxine—hypothyroidism	0.00108	0.00528	CcSEcCtD
Amphetamine—Fatigue—Liotrix—hypothyroidism	0.00108	0.00526	CcSEcCtD
Amphetamine—Rash—Dextrothyroxine—hypothyroidism	0.00107	0.00523	CcSEcCtD
Amphetamine—Rash—Levothyroxine—hypothyroidism	0.00107	0.00523	CcSEcCtD
Amphetamine—Dermatitis—Dextrothyroxine—hypothyroidism	0.00107	0.00523	CcSEcCtD
Amphetamine—Dermatitis—Levothyroxine—hypothyroidism	0.00107	0.00523	CcSEcCtD
Amphetamine—Constipation—Liotrix—hypothyroidism	0.00107	0.00522	CcSEcCtD
Amphetamine—Headache—Dextrothyroxine—hypothyroidism	0.00107	0.0052	CcSEcCtD
Amphetamine—Headache—Levothyroxine—hypothyroidism	0.00107	0.0052	CcSEcCtD
Amphetamine—SLC22A3—female gonad—hypothyroidism	0.00106	0.00852	CbGeAlD
Amphetamine—MAOB—adrenal gland—hypothyroidism	0.00105	0.00845	CbGeAlD
Amphetamine—MAOB—blood—hypothyroidism	0.00105	0.00845	CbGeAlD
Amphetamine—Gastrointestinal pain—Liotrix—hypothyroidism	0.00103	0.00499	CcSEcCtD
Amphetamine—Nausea—Dextrothyroxine—hypothyroidism	0.00101	0.00493	CcSEcCtD
Amphetamine—Nausea—Levothyroxine—hypothyroidism	0.00101	0.00493	CcSEcCtD
Amphetamine—MAOB—thyroid gland—hypothyroidism	0.00101	0.00816	CbGeAlD
Amphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.00101	0.0117	CbGpPWpGaD
Amphetamine—Urticaria—Liotrix—hypothyroidism	0.000996	0.00485	CcSEcCtD
Amphetamine—SLC6A3—testis—hypothyroidism	0.000996	0.00803	CbGeAlD
Amphetamine—Body temperature increased—Liotrix—hypothyroidism	0.000991	0.00483	CcSEcCtD
Amphetamine—Abdominal pain—Liotrix—hypothyroidism	0.000991	0.00483	CcSEcCtD
Amphetamine—DRD2—pituitary gland—hypothyroidism	0.000991	0.00799	CbGeAlD
Amphetamine—MAOB—female gonad—hypothyroidism	0.000978	0.00788	CbGeAlD
Amphetamine—SLC6A2—adrenal gland—hypothyroidism	0.000971	0.00783	CbGeAlD
Amphetamine—SLC6A4—NRF2 pathway—SLC5A7—hypothyroidism	0.000954	0.0111	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.000948	0.011	CbGpPWpGaD
Amphetamine—SLC22A3—testis—hypothyroidism	0.000937	0.00756	CbGeAlD
Amphetamine—Hypersensitivity—Liotrix—hypothyroidism	0.000924	0.0045	CcSEcCtD
Amphetamine—SLC22A5—pituitary gland—hypothyroidism	0.000923	0.00744	CbGeAlD
Amphetamine—SLC6A3—cerebellum—hypothyroidism	0.00092	0.00741	CbGeAlD
Amphetamine—Asthenia—Liotrix—hypothyroidism	0.000899	0.00438	CcSEcCtD
Amphetamine—TAAR1—G alpha (s) signalling events—AVP—hypothyroidism	0.000897	0.0104	CbGpPWpGaD
Amphetamine—SLC22A3—liver—hypothyroidism	0.000886	0.00714	CbGeAlD
Amphetamine—MAOB—testis—hypothyroidism	0.000868	0.00699	CbGeAlD
Amphetamine—Diarrhoea—Liotrix—hypothyroidism	0.000858	0.00418	CcSEcCtD
Amphetamine—Dizziness—Liotrix—hypothyroidism	0.000829	0.00404	CcSEcCtD
Amphetamine—SLC22A5—adrenal gland—hypothyroidism	0.000824	0.00664	CbGeAlD
Amphetamine—SLC22A5—blood—hypothyroidism	0.000824	0.00664	CbGeAlD
Amphetamine—SLC6A2—NRF2 pathway—SLC5A7—hypothyroidism	0.00082	0.00951	CbGpPWpGaD
Amphetamine—MAOB—liver—hypothyroidism	0.00082	0.00661	CbGeAlD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000814	0.00944	CbGpPWpGaD
Amphetamine—SLC6A2—testis—hypothyroidism	0.000803	0.00647	CbGeAlD
Amphetamine—MAOB—cerebellum—hypothyroidism	0.000801	0.00646	CbGeAlD
Amphetamine—Vomiting—Liotrix—hypothyroidism	0.000797	0.00388	CcSEcCtD
Amphetamine—SLC22A5—thyroid gland—hypothyroidism	0.000795	0.00641	CbGeAlD
Amphetamine—Rash—Liotrix—hypothyroidism	0.00079	0.00385	CcSEcCtD
Amphetamine—Dermatitis—Liotrix—hypothyroidism	0.00079	0.00385	CcSEcCtD
Amphetamine—Headache—Liotrix—hypothyroidism	0.000785	0.00383	CcSEcCtD
Amphetamine—SLC22A5—female gonad—hypothyroidism	0.000769	0.00619	CbGeAlD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000768	0.0089	CbGpPWpGaD
Amphetamine—Nausea—Liotrix—hypothyroidism	0.000745	0.00363	CcSEcCtD
Amphetamine—DRD2—testis—hypothyroidism	0.000732	0.0059	CbGeAlD
Amphetamine—SLC6A3—NRF2 pathway—SLC5A7—hypothyroidism	0.000727	0.00842	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—SLC5A7—hypothyroidism	0.000726	0.00842	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000726	0.00841	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000726	0.00841	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—THRB—hypothyroidism	0.000715	0.00829	CbGpPWpGaD
Amphetamine—SLC22A5—testis—hypothyroidism	0.000682	0.00549	CbGeAlD
Amphetamine—DRD2—cerebellum—hypothyroidism	0.000676	0.00545	CbGeAlD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000664	0.0077	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000662	0.00767	CbGpPWpGaD
Amphetamine—SLC22A5—liver—hypothyroidism	0.000644	0.00519	CbGeAlD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000637	0.00738	CbGpPWpGaD
Amphetamine—SLC22A5—cerebellum—hypothyroidism	0.00063	0.00507	CbGeAlD
Amphetamine—TAAR1—GPCR ligand binding—TRH—hypothyroidism	0.00062	0.00719	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—NKX2-1—hypothyroidism	0.000612	0.00709	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000611	0.00708	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—SLC5A7—hypothyroidism	0.000607	0.00703	CbGpPWpGaD
Amphetamine—TAAR1—G alpha (s) signalling events—POMC—hypothyroidism	0.000596	0.00691	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.000565	0.00655	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—TSHR—hypothyroidism	0.000553	0.00641	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—TSHB—hypothyroidism	0.000553	0.00641	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000551	0.00638	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000549	0.00636	CbGpPWpGaD
Amphetamine—CYP2D6—blood—hypothyroidism	0.000532	0.00429	CbGeAlD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000517	0.00599	CbGpPWpGaD
Amphetamine—CYP2D6—female gonad—hypothyroidism	0.000496	0.004	CbGeAlD
Amphetamine—SLC18A2—Neuronal System—NEFL—hypothyroidism	0.000468	0.00542	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000458	0.00531	CbGpPWpGaD
Amphetamine—CYP2D6—testis—hypothyroidism	0.00044	0.00355	CbGeAlD
Amphetamine—SLC6A3—Neuronal System—SLC5A7—hypothyroidism	0.000433	0.00502	CbGpPWpGaD
Amphetamine—MAOB—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.00043	0.00499	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000428	0.00496	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000428	0.00496	CbGpPWpGaD
Amphetamine—CYP2D6—liver—hypothyroidism	0.000416	0.00335	CbGeAlD
Amphetamine—CYP2D6—cerebellum—hypothyroidism	0.000406	0.00327	CbGeAlD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.00039	0.00452	CbGpPWpGaD
Amphetamine—SLC6A4—NRF2 pathway—SLC5A5—hypothyroidism	0.000381	0.00442	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.00038	0.0044	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—NKX2-1—hypothyroidism	0.000374	0.00434	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000364	0.00422	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—TRH—hypothyroidism	0.00035	0.00406	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000338	0.00391	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000337	0.0039	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—SLC5A5—hypothyroidism	0.000328	0.0038	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—AVP—hypothyroidism	0.000326	0.00378	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000324	0.00375	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—TRH—hypothyroidism	0.000318	0.00369	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—TSHB—hypothyroidism	0.000312	0.00362	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—TSHR—hypothyroidism	0.000312	0.00362	CbGpPWpGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000307	0.00356	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—SLC5A5—hypothyroidism	0.00029	0.00337	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—AVP—hypothyroidism	0.000285	0.0033	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000284	0.00329	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—TSHB—hypothyroidism	0.000284	0.00329	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—TSHR—hypothyroidism	0.000284	0.00329	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.00028	0.00324	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—NEFL—hypothyroidism	0.000279	0.00323	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000279	0.00323	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—IYD—hypothyroidism	0.00027	0.00313	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000266	0.00308	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000265	0.00307	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000263	0.00304	CbGpPWpGaD
Amphetamine—CYP2A6—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000259	0.003	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—SLC5A5—hypothyroidism	0.000243	0.00281	CbGpPWpGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000242	0.0028	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000233	0.0027	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—AVP—hypothyroidism	0.000232	0.00269	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ATP5O—hypothyroidism	0.000229	0.00266	CbGpPWpGaD
Amphetamine—MAOB—Biological oxidations—POMC—hypothyroidism	0.000229	0.00265	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—IYD—hypothyroidism	0.000228	0.00264	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000218	0.00252	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CLTC—hypothyroidism	0.000218	0.00252	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—POMC—hypothyroidism	0.000217	0.00251	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—TPO—hypothyroidism	0.000216	0.0025	CbGpPWpGaD
Amphetamine—CYP2A6—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.00021	0.00243	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000209	0.00242	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000208	0.00242	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000207	0.00239	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ATP5O—hypothyroidism	0.000194	0.00225	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000193	0.00223	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—VAV3—hypothyroidism	0.000191	0.00221	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.00019	0.0022	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TRH—hypothyroidism	0.000188	0.00218	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—AVP—hypothyroidism	0.000184	0.00213	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000183	0.00212	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—TPO—hypothyroidism	0.000182	0.00211	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—VAV3—hypothyroidism	0.000174	0.00201	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000169	0.00196	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000169	0.00196	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TSHB—hypothyroidism	0.000168	0.00194	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TSHR—hypothyroidism	0.000168	0.00194	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—AVP—hypothyroidism	0.000167	0.00194	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000163	0.00189	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000156	0.00181	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SH2B3—hypothyroidism	0.000149	0.00173	CbGpPWpGaD
Amphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000145	0.00168	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—TRH—hypothyroidism	0.000145	0.00168	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000144	0.00167	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—AVP—hypothyroidism	0.000142	0.00165	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000135	0.00156	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000135	0.00156	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—IYD—hypothyroidism	0.000131	0.00152	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—TSHB—hypothyroidism	0.000129	0.00149	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—TSHR—hypothyroidism	0.000129	0.00149	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000123	0.00142	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—POMC—hypothyroidism	0.000122	0.00142	CbGpPWpGaD
Amphetamine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000118	0.00136	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ATP5O—hypothyroidism	0.000112	0.00129	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—POMC—hypothyroidism	0.000111	0.00129	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—POMC—hypothyroidism	0.000111	0.00129	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PRL—hypothyroidism	0.000111	0.00128	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000106	0.00123	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000106	0.00123	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—TPO—hypothyroidism	0.000105	0.00122	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000105	0.00122	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VAV3—hypothyroidism	0.000103	0.00119	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—TSHB—hypothyroidism	9.98e-05	0.00116	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	9.98e-05	0.00116	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AVP—hypothyroidism	9.88e-05	0.00114	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	9.3e-05	0.00108	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3C2A—hypothyroidism	8.9e-05	0.00103	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—TSHB—hypothyroidism	8.44e-05	0.000979	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—POMC—hypothyroidism	8.34e-05	0.000966	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—AVP—hypothyroidism	8.27e-05	0.000958	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—TRH—hypothyroidism	8.17e-05	0.000947	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—AVP—hypothyroidism	7.6e-05	0.000881	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3C2A—hypothyroidism	7.53e-05	0.000872	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—SLC5A5—hypothyroidism	7.47e-05	0.000866	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—TRH—hypothyroidism	7.42e-05	0.00086	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—IYD—hypothyroidism	7.37e-05	0.000854	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—AVP—hypothyroidism	7.32e-05	0.000849	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—TSHR—hypothyroidism	7.29e-05	0.000844	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—TSHB—hypothyroidism	7.29e-05	0.000844	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	6.63e-05	0.000768	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—TSHR—hypothyroidism	6.62e-05	0.000767	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—TSHB—hypothyroidism	6.62e-05	0.000767	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—POMC—hypothyroidism	6.56e-05	0.000761	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—SLC5A5—hypothyroidism	6.32e-05	0.000733	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IGF1—hypothyroidism	6.31e-05	0.000732	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ATP5O—hypothyroidism	6.26e-05	0.000726	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—POMC—hypothyroidism	6.24e-05	0.000724	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—TPO—hypothyroidism	5.89e-05	0.000682	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CLTC—hypothyroidism	5.07e-05	0.000588	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—POMC—hypothyroidism	5.05e-05	0.000585	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—TSHB—hypothyroidism	4.86e-05	0.000563	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—VAV3—hypothyroidism	4.46e-05	0.000516	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TRH—hypothyroidism	4.39e-05	0.000508	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3C2A—hypothyroidism	4.33e-05	0.000502	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AVP—hypothyroidism	4.29e-05	0.000498	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—VAV3—hypothyroidism	4.05e-05	0.000469	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—POMC—hypothyroidism	3.91e-05	0.000453	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TSHB—hypothyroidism	3.91e-05	0.000453	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TSHR—hypothyroidism	3.91e-05	0.000453	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AVP—hypothyroidism	3.9e-05	0.000452	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SLC5A5—hypothyroidism	3.64e-05	0.000422	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SH2B3—hypothyroidism	3.48e-05	0.000404	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—POMC—hypothyroidism	3.31e-05	0.000383	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—POMC—hypothyroidism	2.85e-05	0.000331	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—TSHB—hypothyroidism	2.73e-05	0.000316	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—POMC—hypothyroidism	2.59e-05	0.0003	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PRL—hypothyroidism	2.58e-05	0.000299	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3C2A—hypothyroidism	2.43e-05	0.000282	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VAV3—hypothyroidism	2.39e-05	0.000277	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AVP—hypothyroidism	2.3e-05	0.000267	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC5A5—hypothyroidism	2.04e-05	0.000237	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—POMC—hypothyroidism	1.9e-05	0.000221	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—POMC—hypothyroidism	1.53e-05	0.000177	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF1—hypothyroidism	1.47e-05	0.000171	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—POMC—hypothyroidism	1.07e-05	0.000124	CbGpPWpGaD
